Uncover key drivers, emerging technologies, and competitive movements shaping the allogeneic t cell therapies market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Allogeneic T Cell Therapies Market by the end of 2030?
The market size for allogeneic t cell therapies has shown robust expansion in recent years. Looking ahead, it is projected to expand from $1.26 billion in 2025 to $1.38 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. Historically, this expansion can be linked to factors such as the limitations associated with autologous therapies, the initial successes of CAR-T treatments, increasing cancer prevalence, breakthroughs in immunotherapy research, and the expansion of hospital-based oncology facilities.
The allogeneic t cell therapies market is projected to demonstrate robust expansion in the near future. It is forecast to achieve a size of $1.98 billion by 2030, progressing at a compound annual growth rate (CAGR) of 9.4%. This upward trajectory in the forecast period can be attributed to the rising demand for economical cell therapies, the expanding array of oncology pipelines, enhancements in donor matching, supportive regulatory frameworks for cell therapies, and an increase in specialty cancer centers. Prominent trends for this period include a transition toward readily available off-the-shelf cell therapies, an uptick in oncology clinical trials, a stronger emphasis on scalable cell manufacturing, heightened investment in cell engineering, and the proliferation of specialized treatment centers.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp
What Drivers Are Shaping Future Opportunities In The Allogeneic T Cell Therapies Market?
The escalating number of cancer cases is anticipated to drive the allogeneic T cell therapies market forward. Cancer encompasses a range of diseases defined by the unchecked proliferation and dissemination of abnormal cells within the body. The uptick in cancer cases stems from various factors, including extended lifespans, lifestyle modifications, environmental influences, infections, inherited traits, and altered reproductive patterns. Allogeneic T cell therapies are administered to cancer patients to target and eliminate malignant cells through the infusion of genetically modified donor T cells designed to recognize specific tumor antigens. For example, according to the National Cancer Institute, a US-based government agency, there were about 18.1 million cancer survivors in the United States in May 2024. This number is predicted to climb to 22.5 million by 2032. By 2040, new cancer diagnoses are expected to reach 29.9 million annually, with cancer-related fatalities projected to increase to 15.3 million. Thus, the increasing incidence of cancer is a key driver for the allogeneic T cell therapies market.
Which Segment Groups Are Influencing The Allogeneic T Cell Therapies Market?
The allogeneic t cell therapies market covered in this report is segmented –
1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies
2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types
3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Other Therapeutics Indications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies
2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies
What Trends Are Expected To Impact The Competitive Landscape Of The Allogeneic T Cell Therapies Market?
Major companies active in the allogeneic T cell therapies market are concentrating on developing advanced products, such as gene-edited donor-derived CAR-T and TCR T cell treatments, to gain a competitive advantage. Gene-edited donor-derived T cell therapies are defined as immune-effector T cells originating from healthy donors that undergo genetic manipulation (e.g., inactivation of T cell receptor (TCR) and HLA genes, incorporation of CAR/TCR constructs, and inclusion of safety switches) to create universal, off-the-shelf products. These products can be manufactured in large quantities, cryopreserved, and administered quickly without needing patient-specific production. For instance, in January 2024, Allogene Therapeutics, a US-based cell therapy company, announced its 2024 platform vision centered on ALPHA3, which is the industry’s first pivotal trial for an allogeneic CAR-T program utilizing gene-editing technologies to eliminate graft-versus-host disease (GvHD) risk and enable rapid donor-based delivery. The product features include donor-derived T cells edited to remove endogenous TCR and HLA molecules, thus reducing host immune rejection and GvHD. It also incorporates a chimeric antigen receptor targeting a tumor antigen for prompt anti-cancer activity and comes in a cryopreserved, ready-to-infuse format to shorten time to treatment compared to autologous therapies.
Who Are The Prominent Global Companies Shaping The Allogeneic T Cell Therapies Market Landscape?
Major companies operating in the allogeneic t cell therapies market are Allogene Therapeutics Inc., Cellectis SA, Fate Therapeutics Inc., Poseida Therapeutics Inc., Atara Biotherapeutics Inc., Autolus Therapeutics Plc, Adaptimmune Therapeutics Plc, Immatics NV, Medigene AG, Celyad Oncology SA, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Sangamo Therapeutics Inc., MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Bellicum Pharmaceuticals Inc., Enlivex Therapeutics Ltd., Sorrento Therapeutics Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report
Which Geographic Areas Are Emerging As Strong Markets For The Allogeneic T Cell Therapies Market?
North America was the largest region in the allogeneic T cell therapies market in 2025. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Allogeneic T Cell Therapies Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18952&type=smp
Browse Through More Reports Similar to the Global Allogeneic T Cell Therapies Market 2026, By The Business Research Company
Allogeneic Cell Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report
Cells Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report
Cell Therapy Technologies Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model